SYNLOGIC, INC. Operating Expenses
SYNLOGIC, INC. (SYBX) reported Operating Expenses of $1.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- SYNLOGIC, INC. operating expenses for the quarter ending 2026-06-30 was $1.01M, a 30.24% increase year-over-year.
- SYNLOGIC, INC. operating expenses for the quarter ending 2026-03-31 was $1.32M, a 46.88% increase year-over-year.
- SYNLOGIC, INC. operating expenses for the quarter ending 2025-12-31 was $1.34M, a 24.44% decline year-over-year.
- SYNLOGIC, INC. operating expenses for the quarter ending 2025-09-30 was $991.00K, a 32.49% increase year-over-year.
- SYNLOGIC, INC. operating expenses for fiscal 2025 was $4.01M, a 90.21% decline from fiscal 2024.
- SYNLOGIC, INC. operating expenses for fiscal 2024 was $40.96M, a 30.02% decline from fiscal 2023.
- SYNLOGIC, INC. operating expenses for fiscal 2023 was $58.53M, a 14.68% decline from fiscal 2022.
- SYNLOGIC, INC. operating expenses for fiscal 2022 was $68.60M, a 9.73% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.01M 10-Q · filed 2026-08-11 | $2.33M 10-Q · filed 2026-08-11 | $3.67M derived: sum of 3 quarters · filed 2026-08-11 | $4.66M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $1.32M 10-Q · filed 2026-05-14 | $2.66M derived: sum of 2 quarters · filed 2026-05-14 | $3.65M derived: sum of 3 quarters · filed 2026-05-14 | $4.43M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.33M derived: sum of 2 quarters · filed 2026-03-12 | $3.11M derived: sum of 3 quarters · filed 2026-08-11 | $4.01M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $991.00K 10-Q · filed 2025-11-13 | $1.77M derived: sum of 2 quarters · filed 2026-08-11 | $2.67M 10-Q · filed 2025-11-13 | $4.44M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $777.00K 10-Q · filed 2026-08-11 | $1.68M 10-Q · filed 2026-08-11 | $3.45M derived: sum of 3 quarters · filed 2026-08-11 | $4.20M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $898.00K 10-Q · filed 2026-05-14 | $2.67M derived: sum of 2 quarters · filed 2026-05-14 | $3.42M derived: sum of 3 quarters · filed 2026-05-14 | $3.00M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.52M derived: sum of 2 quarters · filed 2026-03-12 | $2.10M derived: sum of 3 quarters · filed 2026-03-12 | $40.96M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $748.00K 10-Q · filed 2025-11-13 | $329.00K derived: sum of 2 quarters · filed 2025-11-13 | $39.18M 10-Q · filed 2025-11-13 | $52.59M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$419.00K 10-Q · filed 2025-08-07 | $38.43M 10-Q · filed 2025-08-07 | $51.84M derived: sum of 3 quarters · filed 2025-08-07 | $64.86M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $38.85M 10-Q · filed 2025-05-08 | $52.26M derived: sum of 2 quarters · filed 2025-05-08 | $65.28M derived: sum of 3 quarters · filed 2025-05-08 | $80.97M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $13.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $26.43M derived: sum of 2 quarters · filed 2025-03-06 | $42.12M derived: sum of 3 quarters · filed 2025-03-06 | $58.53M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | $13.02M 10-Q · filed 2024-11-12 | $28.70M derived: sum of 2 quarters · filed 2024-11-12 | $45.12M 10-Q · filed 2024-11-12 | $62.53M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $15.69M 10-Q · filed 2024-08-08 | $32.11M 10-Q · filed 2024-08-08 | $49.52M derived: sum of 3 quarters · filed 2024-08-08 | $68.53M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $16.42M 10-Q · filed 2024-05-14 | $33.83M derived: sum of 2 quarters · filed 2024-05-14 | $52.84M derived: sum of 3 quarters · filed 2024-05-14 | $69.01M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $17.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $36.42M derived: sum of 2 quarters · filed 2024-03-19 | $52.59M derived: sum of 3 quarters · filed 2024-03-19 | $68.60M 10-K · filed 2024-03-19 | ||||
| 2022-09-30 | $19.01M 10-Q · filed 2023-11-09 | $35.18M derived: sum of 2 quarters · filed 2023-11-09 | $51.19M 10-Q · filed 2023-11-09 | $66.93M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | $16.17M 10-Q · filed 2023-08-10 | $32.18M 10-Q · filed 2023-08-10 | $47.91M derived: sum of 3 quarters · filed 2023-08-10 | $64.89M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $16.01M 10-Q · filed 2023-05-11 | $31.75M derived: sum of 2 quarters · filed 2023-05-11 | $48.72M derived: sum of 3 quarters · filed 2023-05-11 | $63.50M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $15.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $32.71M derived: sum of 2 quarters · filed 2023-03-29 | $47.49M derived: sum of 3 quarters · filed 2023-03-29 | $62.52M 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | $16.97M 10-Q · filed 2022-11-10 | $31.75M derived: sum of 2 quarters · filed 2022-11-10 | $46.78M 10-Q · filed 2022-11-10 | $61.48M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $14.78M 10-Q · filed 2022-08-11 | $29.81M 10-Q · filed 2022-08-11 | $44.51M derived: sum of 3 quarters · filed 2022-08-11 | $57.94M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $15.03M 10-Q · filed 2022-05-12 | $29.73M derived: sum of 2 quarters · filed 2022-05-12 | $43.16M derived: sum of 3 quarters · filed 2022-05-12 | $59.54M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $14.69M 10-K · filed 2021-03-25 | $28.13M derived: sum of 2 quarters · filed 2021-11-10 | $44.51M derived: sum of 3 quarters · filed 2021-11-10 | $61.01M 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $13.44M 10-Q · filed 2021-11-10 | $29.82M derived: sum of 2 quarters · filed 2021-11-10 | $46.32M 10-Q · filed 2021-11-10 | $61.03M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $16.38M 10-Q · filed 2021-08-12 | $32.88M 10-Q · filed 2021-08-12 | $47.59M derived: sum of 3 quarters · filed 2021-08-12 | $62.03M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $16.50M 10-Q · filed 2021-05-13 | $31.21M derived: sum of 2 quarters · filed 2021-05-13 | $45.65M derived: sum of 3 quarters · filed 2021-05-13 | $59.10M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | $14.71M 10-K · filed 2021-03-25 | $29.15M derived: sum of 2 quarters · filed 2021-03-25 | $42.60M derived: sum of 3 quarters · filed 2021-03-25 | $56.63M 10-K · filed 2021-03-25 | ||||
| 2019-09-30 | $14.44M 10-K · filed 2021-03-25 | $27.89M derived: sum of 2 quarters · filed 2021-03-25 | $41.92M 10-Q · filed 2020-11-05 | $54.74M derived: sum of 4 quarters · filed 2021-03-25 | ||||
| 2019-06-30 | $13.45M 10-K · filed 2021-03-25 | $27.48M 10-Q · filed 2020-08-06 | $40.30M derived: sum of 3 quarters · filed 2021-03-25 | $53.63M derived: sum of 4 quarters · filed 2021-03-25 | ||||
| 2019-03-31 | $14.04M 10-K · filed 2021-03-25 | $26.85M derived: sum of 2 quarters · filed 2021-03-25 | $40.19M derived: sum of 3 quarters · filed 2021-03-25 | $55.80M derived: sum of 4 quarters · filed 2021-03-25 | ||||
| 2018-12-31 | $12.82M 10-K · filed 2020-03-12 | $26.15M derived: sum of 2 quarters · filed 2020-03-12 | $41.76M derived: sum of 3 quarters · filed 2020-03-12 | $53.75M 10-K · filed 2020-03-12 | ||||
| 2018-09-30 | $13.34M 10-K · filed 2020-03-12 | $28.94M derived: sum of 2 quarters · filed 2020-03-12 | $40.93M 10-Q · filed 2019-11-12 | $52.96M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-06-30 | $15.61M 10-K · filed 2020-03-12 | $27.60M 10-Q · filed 2019-08-08 | $39.63M derived: sum of 3 quarters · filed 2020-03-12 | $51.81M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-03-31 | $11.99M 10-K · filed 2020-03-12 | $24.02M derived: sum of 2 quarters · filed 2020-03-12 | $36.20M derived: sum of 3 quarters · filed 2020-03-12 | $47.77M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2017-12-31 | $12.03M 10-K · filed 2019-03-12 | $24.21M derived: sum of 2 quarters · filed 2019-03-12 | $35.78M derived: sum of 3 quarters · filed 2019-03-12 | $43.27M 10-K · filed 2019-03-12 | ||||
| 2017-09-30 | $12.19M 10-K · filed 2019-03-12 | $23.75M derived: sum of 2 quarters · filed 2019-03-12 | $31.24M 10-Q · filed 2018-11-13 | $38.21M derived: sum of 4 quarters · filed 2019-03-12 | ||||
| 2017-06-30 | $11.57M 10-K · filed 2019-03-12 | $9.48M 10-Q · filed 2017-08-04 | $19.05M 10-Q · filed 2018-08-09 | $14.54M 10-Q · filed 2017-08-04 | $26.02M derived: sum of 3 quarters · filed 2019-03-12 | $31.44M derived: sum of 4 quarters · filed 2019-03-12 | ||
| 2017-03-31 | $7.49M 10-K · filed 2019-03-12 | $5.06M 10-Q · filed 2017-05-09 | $14.46M derived: sum of 2 quarters · filed 2019-03-12 | $19.87M derived: sum of 3 quarters · filed 2019-03-12 | $24.96M derived: sum of 4 quarters · filed 2019-03-12 | |||
| 2016-12-31 | $6.97M 10-K · filed 2018-03-20 | $8.78M 10-K · filed 2017-03-15 | $12.39M derived: sum of 2 quarters · filed 2018-03-20 | $17.47M derived: sum of 3 quarters · filed 2018-03-20 | $21.41M 10-K · filed 2018-03-20 | $26.62M 10-K · filed 2017-03-15 | ||
| 2016-09-30 | $5.42M 10-K · filed 2018-03-20 | $5.32M 10-Q · filed 2016-11-10 | $10.50M derived: sum of 2 quarters · filed 2018-03-20 | $14.44M 10-Q · filed 2017-11-13 | $17.71M 10-Q · filed 2016-11-10 | $23.26M derived: sum of 4 quarters · filed 2018-03-20 | ||
| 2016-06-30 | $5.08M 10-K · filed 2018-03-20 | $5.73M 10-Q · filed 2016-08-15 | $12.38M 10-Q · filed 2017-08-04 | $17.84M derived: sum of 3 quarters · filed 2018-03-20 | $24.08M derived: sum of 4 quarters · filed 2018-03-20 | |||
| 2016-03-31 | $3.94M 10-K · filed 2018-03-20 | $6.65M 10-Q · filed 2016-05-12 | $12.76M derived: sum of 2 quarters · filed 2018-03-20 | $19.00M derived: sum of 3 quarters · filed 2018-03-20 | $24.68M derived: sum of 4 quarters · filed 2018-03-20 | |||
| 2015-12-31 | $8.82M 10-K · filed 2017-03-15 | $15.06M derived: sum of 2 quarters · filed 2017-03-15 | $20.75M derived: sum of 3 quarters · filed 2017-03-15 | $25.03M 10-K · filed 2017-03-15 | ||||
| 2015-09-30 | $6.24M 10-K · filed 2017-03-15 | $11.92M derived: sum of 2 quarters · filed 2017-03-15 | $16.20M 10-Q · filed 2016-11-10 | $20.58M derived: sum of 4 quarters · filed 2017-03-15 | ||||
| 2015-06-30 | $5.68M 10-K · filed 2017-03-15 | $9.96M 10-Q · filed 2016-08-15 | $14.34M derived: sum of 3 quarters · filed 2017-03-15 | $19.76M derived: sum of 4 quarters · filed 2017-03-15 | ||||
| 2015-03-31 | $4.28M 10-K · filed 2017-03-15 | $8.66M derived: sum of 2 quarters · filed 2017-03-15 | $14.08M derived: sum of 3 quarters · filed 2017-03-15 | $17.08M derived: sum of 4 quarters · filed 2017-03-15 | ||||
| 2014-12-31 | $4.38M 10-K · filed 2016-03-30 | $9.80M derived: sum of 2 quarters · filed 2016-03-30 | $12.80M derived: sum of 3 quarters · filed 2016-03-30 | $15.83M 10-K · filed 2017-03-15 | ||||
| 2014-09-30 | $5.42M 10-K · filed 2016-03-30 | $8.42M derived: sum of 2 quarters · filed 2016-03-30 | $11.46M 10-Q · filed 2015-11-13 | |||||
| 2014-06-30 | $3.00M 10-K · filed 2016-03-30 | $6.03M derived: sum of 2 quarters · filed 2016-03-30 | ||||||
| 2014-03-31 | $3.04M 10-K · filed 2016-03-30 | |||||||
| 2013-12-31 | $6.78M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |